… Histone deacetylase inhibitors (HDACi) represent a … models of prostate cancer. In vitro
proliferation assays demonstrated that belinostat potently inhibited the growth of prostate cancer …

… prostate cancer cell lines. Then, we tested the antitumor activity of MS-275 in several prostate
cancer models … and intratibia xenografts, and transgenic mice developing prostate cancers. …

… Histone deacetylase (HDAC) inhibitors have been reported to have … I specific HDAC inhibitor,
entinostat, in combination with either IL-2 in a murine renal cell carcinoma (RENCA) model …

… currently in clinical trials, was evaluated in prostate cancer models in vitro and in vivo. We
show here that (S)-HDAC-42 is a potent inhibitor of prostate cancer cell viability and induces a …

… that showed inhibition of HDAC activity and cancer cell … VPA-derivatives in a prostate
cancer model. In vivo, western … growth inhibition and intra-tumour histone H3 acetylation. …

… Histone deacetylase inhibitors sensitize prostate cancer … histone deacetylase inhibitor,
blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model…

… advantageous in the context of cancer prevention. Here, we … HDAC inhibitor, on prostate
tumor progression in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model. …

… activity of SAHA in three prostate cancer cell lines (LNCaP, … the CWR22 human prostate
cancer xenograft model in nude … Hybrid polar histone deacetylase inhibitor induces apoptosis …

… (HDAC) and histone acetyltransferase (HAT) enzymes. Histone deacetylase inhibitors (HDACi)
show great promise in preclinical cancer models, but clinical trials treating solid tumors …

… others that histone deacetylase (HDAC) inhibitors have a … and that these agents inhibit
prostate cancer cell growth.10, 11 … of HDAC3 inhibitors in relevant models of prostate cancer we …